Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]
News [1431]
Articles [66]
Editorials [2]
Conferences [72]
elearning [5]
Ipilimumab may improve outlook of metastatic melanoma in the elderly
Dr Antonio Grimaldi – National Cancer Institute of Napoli, Italy
Ipilimumab may improve outlook of metastatic melanoma in the elderly ( Dr Antonio Grimaldi – National Cancer Institute of Napoli, Italy )
28 Oct 2014
ESMO 2014: News Roundup
ecancer News Team
ESMO 2014: News Roundup ( ecancer News Team )
16 Oct 2014
ESMO 2014 Editor's roundup
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ESMO 2014 Editor's roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
8 Oct 2014
Ipilimumab extends relapse-free survival in resectable melanoma
Prof Alexander Eggermont - Gustave Roussy, Villejuif, France
Ipilimumab extends relapse-free survival in resectable melanoma ( Prof Alexander Eggermont - Gustave Roussy, Villejuif, France )
2 Oct 2014
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
Dr Caroline Robert - Gustave Roussy, Villejuif, France
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )
29 Sep 2014
Nivolumab potentially superior to standard chemo in advanced melanoma
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab potentially superior to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
29 Sep 2014
Improved response rate and survival with dabrafenib plus trametinib versus...
Dr Caroline Robert - Gustave Roussy, Villejuif, France
Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )
29 Sep 2014
Vemurafenib plus cobimetinib achieves significant progression-free survival in...
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2014
Nivolumab shows signs of superior response rate compared to standard chemo in...
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
29 Sep 2014
Combining cobimetinib and vemurafenib improves progression-free survival in...
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Sep 2014
Benefits of investing in skin cancer prevention
Craig Sinclair - Cancer Council Victoria, Victoria, Australia
Benefits of investing in skin cancer prevention ( Craig Sinclair - Cancer Council Victoria, Victoria, Australia )
11 Sep 2014
Preventing skin cancer worldwide and the impact of different regulatory and...
Prof Darrell Rigel - New York University Medical Center, New York, USA
Preventing skin cancer worldwide and the impact of different regulatory and economic priorities ( Prof Darrell Rigel - New York University Medical Center, New York, USA )
11 Sep 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation